EyePoint Pharmaceuticals Climbs 38% Following Outperform Rating

Jefferies upgrades this multinational on continued growth in the aerospace sector
April 20, 2023
Warning: SQM is at high risk of cutting its dividend
April 22, 2023
0

EyePoint Pharmaceuticals Climbs 38% Following Outperform Rating

[ad_1]


EyePoint Pharmaceuticals Climbs 38% Following Outperform Rating

[ad_2]

Source link

Related posts

April 16, 2024

European markets slump on rising Middle-East tensions

Read more
April 15, 2024

Exclusive-Poland focusing on EU recovery grants, law change to ramp up investments

Read more
April 14, 2024

Sirens and blasts sound across Israel after Iran launches drone attack

Read more
April 13, 2024

No evidence Ozempic and Wegovy raise risk of self harm, EU regulators said

Read more
April 12, 2024

Universal Technical partners with iRacing

Read more
April 11, 2024

AstraZeneca announces dividend hike ahead of CEO pay vote

Read more

Leave a Reply

Your email address will not be published. Required fields are marked *